Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 26.

Sculier, D; Doco-Lecompte, T; Yerly, S; Metzner, K J; Decosterd, L A; Calmy, A (2018). Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study. HIV Medicine, 19(8):572-577.

Marzel, A; Shilaih, Mohaned; Turk, T; Campbell, Nottania K; Yang, Wan-Lin; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Calmy, A; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Metzner, K J; Gunthard, H F; Kouyos, R D; Swiss HIV Cohort Study (2017). Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships. HIV Medicine, 18(9):667-676.

Huber, M; Metzner, K J; Geissberger, F D; Shah, C; Leemann, C; Klimkait, T; Böni, J; Trkola, A; Zagordi, O (2017). MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. Journal of Virological Methods, 240:7-13.

Noguera-Julian, M; Cozzi-Lepri, A; Di Giallonardo, F; Schuurman, R; Däumer, M; Aitken, S; Ceccherini-Silberstein, F; D'Arminio Monforte, A; Geretti, A M; Booth, C L; Kaiser, R; Michalik, C; Jansen, K; Masquelier, B; Bellecave, P; Kouyos, R D; Castro, E; Furrer, H; Schultze, A; Günthard, H F; Brun-Vezinet, F; Metzner, K J; Paredes, R (2016). Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 22(2):191-200.

Schaerer, V; Haubitz, S; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, H; Metzner, K J; Fehr, J; Rauch, A (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine, 16(10):599-607.

Zoufaly, A; Jochum, J; Hammerl, R; Nassimi, N; Raymond, Y; Burchard, G D; Schmiedel, S; Drexler, J F; Campbell, N K; Taka, N; Awasom, C; Metzner, K J; van Lunzen, J; Feldt, T (2015). Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. Journal of Antimicrobial Chemotherapy, 70(3):922-925.

Metzner, K J; Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Hirsch, H; Vernazza, P L; Cavassini, M; Calmy, A; Bernasconi, E; Weber, R; Gunthard, H F (2014). Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS, 28(15):2231-2239.

Braun, D L; Rauch, A; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Metzner, K J; Böni, J; Weber, R; Fehr, J (2014). Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Medicine, 15:625-630.

Braun, D l; Rauch, A; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Metzner, K J; Böni, J; Weber, R; Fehr, J (2014). Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. Neurobehavioral HIV Medicine, 15(10):625-630.

Prabhakaran, S; Boehm, A; Metzner, K J; Roth, V (2012). Recovering networks from distance data. Journal of Machine Learning Research, 25:349-364.

Huelsmann, P M; Hofmann, A D; Knoepfel, S A; Popp, J; Rauch, P; Di Giallonardo, F; Danke, C; Gueckel, E; Schambach, A; Wolff, H; Metzner, K J; Berens, C (2011). A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication. BMC Biotechnology, 11:4.

Rieder, P; Joos, B; Scherrer, A U; Kuster, H; Braun, D; Grube, C; Niederöst, B; Leemann, C; Gianella, S; Metzner, K J; Böni, J; Weber, R; Günthard, H F (2011). Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clinical Infectious Diseases, 53(12):1271-1279.

Metzner, K J (2011). Evolution und Diversität von HIV-1. Praxis, 100(1):29-35.

Knoepfel, S A; Di Giallonardo, F; Däumer, M; Thielen, A; Metzner, K J (2011). In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. Journal of Virological Methods, 171(2):329-338.

Li, J Z; Paredes, R; Ribaudo, H J; Svarovskaia, E S; Metzner, K J; Kozal, M J; Hullsiek, K H; Balduin, M; Jakobsen, M R; Geretti, A M; Thiebaut, R; Ostergaard, L; Masquelier, B; Johnson, J A; Miller, M D; Kuritzkes, D R (2011). Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA: The Journal of the American Medical Association, 305(13):1327-1335.

Bansal, V; Metzner, K J; Niederost, B; Leemann, C; Böni, J; Gunthard, H F; Fehr, J S (2011). Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean Immigrant. Emerging Infectious Diseases, 17(10):1966-1968.

Metzner, K J; Rauch, P; Braun, P; Knechten, H; Ehret, R; Korn, K; Kaiser, R; Sichtig, N; Ranneberg, B; van Lunzen, J; Walter, H (2011). Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. Journal of Clinical Virology, 50(2):156-161.

Metzner, K J; Leemann, C; Di Giallonardo, F; Grube, C; Scherrer, A U; Braun, D; Kuster, H; Weber, R; Guenthard, H F (2011). Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. PLoS ONE, 6(7):e21734.

Metzner, K J; Rauch, P; von Wyl, V; Leemann, C; Grube, C; Kuster, H; Böni, J; Weber, R; Günthard, H F (2010). Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. Journal of Infectious Diseases, 201(7):1063-1071.

Schmid, A; Gianella, S; von Wyl, V; Metzner, K J; Scherrer, A U; Niederöst, B; Althaus, C F; Rieder, P; Grube, C; Joos, B; Weber, R; Fischer, M; Günthard, H F (2010). Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS ONE, 5(10):e13310.

Althaus, C F; Gianella, S; Rieder, P; von Wyl, V; Kouyos, R D; Niederöst, B; Schmid, A; Metzner, K J; Joos, B; Günthard, H F; Fischer, M (2010). Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 165(2):151-160.

Drogan, D; Rauch, P; Hoffmann, D; Walter, H; Metzner, K J (2010). The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro. Antiviral Research, 86(3):312-315.

Metzner, K J. Genomic diversity and population dynamics of simian and human immunodeficiency viruses (SIV/HIV). 2009, University of Zurich, Faculty of Medicine.

Metzner, K J; Giulieri, S G; Knoepfel, S A; Rauch, P; Burgisser, P; Yerly, S; Günthard, H F; Cavassini, M (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clinical Infectious Diseases, 48(2):239-247.

Hofmann, C; Harrer, T; Kubesch, V; Maurer, K; Metzner, K J; Eismann, K; Bergmann, S; Schmitt-Haendle, M; Schuler, G; Dörrie, J; Schaft, N (2008). Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA. AIDS, 22(13):1577-1582.

Knoepfel, S A; Salisch, N C; Huelsmann, P M; Rauch, P; Walter, H; Metzner, K J (2008). Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. Journal of Virology, 82(13):6536-6545.

This list was generated on Thu Jun 27 14:21:14 2019 CEST.